^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Gilotrif (afatinib) (pan-HER inhibitor) +
    Koselugo (selumetinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer (M14AFS)

    Excerpt:
    ...Written documentation of a known pathogenic KRAS (exon 2, 3 or 4) mutation and PIK3CA wildtype (defined as absence of mutations in exon 9 and 20)...
    Trial ID:
    M14AFS
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Oncologist
    Title:

    Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer

    Published date:
    12/09/2020
    Excerpt:
    Efficacy was limited with disease stabilization for 221 days in a patient with NSCLC as best response....Afatinib and selumetinib can be combined in continuous and intermittent schedules in patients with KRASmt tumors.
    DOI:
    10.1002/onco.13631
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    Phase I study of afatinib plus selumetinib in patients with KRAS mutation-positive colorectal, non-small cell lung and pancreatic cancer.

    Published date:
    05/13/2020
    Excerpt:
    ...phase I clinical trial was initiated with the combination of the orally administered pan-HER inhibitor afatinib and the MEK inhibitor selumetinib in patients with KRAS mutant and PIK3CA wildtype colorectal cancer (CRC), non-small cell lung cancer (NSCLC), or pancreatic cancer...stable disease for 221 days in a patient with NSCLC as best response.
    DOI:
    10.1200/JCO.2020.38.15_suppl.3613
    Trial ID:
    M14AFS